rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma

Figures & data

Table 1 Patient characteristics

	TPO(n=40)	Control(n=38)	P-value
Mediam (range) Age	39(17–61)	41(18–62)	0.62
Gender (male:female)	27:13	25:13	0.98
Disease stage n (%)
I	0	0	0.53
II	4(10%)	3(7.9%)
III	16(40%)	17(44.7%)
IV	20(50%)	18(47.4%)
Disease status n (%)			0.63
CR	16(40%)	14(36.8%)
PR	16(40%)	18(47.4%)
PD	8(20%)	6(15.8%)
Mediam (range)course of Prior chemotherapy	9(4–22)	8(5–16)	0.17
Prior radiotherapy n(%)	10(25%)	7(18.4%)	0.35
BM involvement n(%)	3(7.5%)	4(10.5%)	0.25

Abbreviation: TPO, Thrombopoietin.

Table 2 Results of PBPC collection

	TPO(n=40)	Control(n=38)	P-value
Total MNC cell(×10^8/kg)	6.89(4.2–17.9)	6.35(3.8–12.1)	0.33
Total CD34+ cell(×10^6/kg)	6.35(2.3–22.7)	3.3(0.5–16.2)	0.0054
Patients meeting successful target(>2×10^6 CD34+ cells/kg)(%)	100%	86%	0.035
Patients meeting optimal target(>5×10^6 CD34+ cells/kg)(%)	72.9%	41.3%	0.021
Median day to apheresis(d)	11(8–14)	11(7–15)	0.79
Number of apheresis	2 (1–3)	2 (1–3)	0.84

Notes: 100% and 86% (the red values) represent the percentage of patients meeting successful target (>2×10⁶ CD34+ cells/kg) in TPO group and Control group, respectively. p<0.05, The difference between the two groups was statistically significant. 72.9% and 41.3% (red values) represent the percentage of Patients meeting optimal target (>5×10⁶ CD34+ cells/kg) in TPO group and Control group, respectively. p<0.05, The difference between the two groups was statistically significant.

Abbreviation: PBPC, peripheral blood progenitor cells.

Table 3 Results of hematopoietic reconstitution

	TPO(n=40)	Control(n=33)	P-value
Neutrophic engrafment(d)	12(8–15)	12(8–14)	0.48
Platelet engrafment(d)	12(11–17)	14(10–16)	0.27
Platelet transfusion events	3(2–5)	4(3–6)	0.088
Red blood cell transfusion events	4(2–6)	4(2–8)	0.332
Patients with infectious fevers	42%	48%	0.93
Fever durations(d)	4(0–6)	3(0–5)	0.882

Abbreviation: TPO, Thrombopoietin.